The Application of DNA Nanomachines for Detecting microRNA in Blood for the Diagnosis of Pancreatic Cancer. Diagnosis of Pancreatic Cancer
NCT ID: NCT06497777
Last Updated: 2024-07-12
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
30 participants
OBSERVATIONAL
2024-07-06
2026-06-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
The Role of MicroRNA in the Diagnosis, Prognosis and Response to Treatment in Pancreatic Cancer
NCT04406831
DNA Mutation Detection in Circulating Tumor DNA and Tissue by mmADPS for Pancreatic Cancer
NCT05604573
Plasma Circulating Deoxyribonucelic Acid (DNA) as a Response Marker
NCT00318604
Circulating Tumor DNA as a Prognostic Marker in Patients With Pancreatic Cancer
NCT03214991
The Difference of microRNA and Circulating Tumor Cells in Blood Among Cancer Patients With Immunotherapy
NCT07260370
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_CONTROL
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Pancreatic adenocarcinoma
Pancreatic adenocarcinoma which are proven by pathology, before initiation of anti-cancer treatment.
MicroRNA (mir-642b-3p)
A circulating microRNA in the blood of pancreatic cancer patients.
Healthy control
People who do not have pancreatic disease.
No interventions assigned to this group
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
MicroRNA (mir-642b-3p)
A circulating microRNA in the blood of pancreatic cancer patients.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Proven by pathology
* Patients who have not received anti-cancer therapies
Exclusion Criteria
* Unable to provide inform and consent
* Patients who have active malignancy other than pancreatic adenocarcinoma
* Patients who have had pancreatic cancer whose anti-cancer therapies are completed or undergoing
* Life expectancy less than 3 months
20 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National Taiwan University Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
National Taiwan University Hospital
Taipei, , Taiwan
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
202405082RINB
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.